The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Trump tariffs on chips and drugs would hit U.S. allies in Asia Worldcategory· January 28, 2025 The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...